# A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis

> **NCT06281704** · PHASE1 · COMPLETED · sponsor: **Akeso** · enrollment: 34 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **BIOLOGICAL:** AK101 IV
- **BIOLOGICAL:** AK101 SC
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** AK101 IV/AK101 SC

## Key facts

- **NCT ID:** NCT06281704
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-26
- **Primary completion:** 2022-05-17
- **Final completion:** 2022-12-31
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06281704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06281704, "A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06281704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*